Terminated NA INTERVENTIONAL 1-arm NCT00477191

Effects of TNF-alpha Antagonism (Etanercept) in Patients With the Metabolic Syndrome and Psoriasis

Sponsor: Amgen

Conditions Hyperlipidemia Hypertension Metabolic Syndrome Obesity Psoriasis

Interventions Etanercept

Updated 8 times since 2017 Last updated: Apr 12, 2016 Started: May 31, 2007 Primary completion: Dec 31, 2013 Completion: Dec 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Difficulty in recruitment.

Other terminated trials from Amgen

See all terminations from Amgen

Other Hyperlipidemia trials with similar outcome

NCT00004466 · Phase PHASE2 · Dec 1999

Browse all Hyperlipidemia trials

Listed as NCT00477191, this NA trial focuses on Hyperlipidemia and Hypertension and remains terminated or withdrawn. Sponsored by Amgen, it has been updated 8 times since 2007, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Terminated NA
Jul 2024 — Sep 2024 [monthly]

Terminated NA
Jan 2023 — Jul 2024 [monthly]

Terminated NA
Dec 2022 — Jan 2023 [monthly]

Terminated NA
Dec 2021 — Dec 2022 [monthly]

Terminated NA

▶ Show 3 earlier versions

Jan 2021 — Dec 2021 [monthly]

Terminated NA
Jun 2018 — Jan 2021 [monthly]

Terminated NA
Jan 2017 — Jun 2018 [monthly]

Terminated NA

First recorded

May 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Amgen
Massachusetts General Hospital

Data source: Massachusetts General Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Boston, United States